Carbapenem is an important therapy for serious hospital‐acquired infections and for the
care of patients affected by multidrug‐resistant organisms, specifically Acinetobacter …

Carbapenem-resistant Acinetobacter baumannii pose a significant threat to hospitalized
patients, as therapeutic options are scarse. Alarmingly, rates of carbapenem-resistance in A …

Acinetobacter baumannii is an opportunistic gram-negative pathogen with increasing
relevance in a variety of nosocomial infections especially among intensive-care-unit (ICU) …

Unprecedented levels of antimicrobial resistance in bacterial isolates have prompted great
concerns globally. In 2012 the WHO released a publication outlining the evolving threat of …

Despite having a reputation of low virulence, Acinetobacter baumannii is an emerging
multidrug-resistant (MDR) pathogen responsible for community-and hospital-acquired …

Acinetobacter baumannii is a Gram-negative, glucose-non-fermenting, oxidase-negative
coccobacillus, most commonly associated with the hospital settings. The ability to survive in …

The increasing number of carbapenem-resistant Acinetobacter baumannii clinical isolates is
a major concern, which restricts therapeutic options for treatment of serious infections …

Acinetobacter baumannii is an important opportunistic pathogen due to its capabilities for
developing mechanisms of resistance to a wide range of antimicrobial agents including …

Carbapenem-resistant Acinetobacter baumannii (CRAB) are an increasing infectious threat
in hospitals. We investigated the clinical epidemiology of CRAB infections vs. colonization in …

Beginning in 1992, a sustained outbreak of multiresistant Acinetobacter baumannii
infections was noted in our 1,000-bed hospital in Barcelona, Spain, resulting in considerable …